This Is Why with Dr. Busti

Anthony Busti, MD, PharmD, MSc, FNLA, FAHA
  • 5.0 (3)
  • EDUCATION

This Is Why exists to help medical professionals understand the why behind the decisions they make every day in patient care. Our approach is about integrating evidence, clinical relevance and real-world application so that what your learn connects directly with the patients you serve. 

  1. 19H AGO

    Practice Question: CHA₂DS₂-VASc Score AF

    CHA₂DS₂-VASc score atrial fibrillation is a critical concept for determining when anticoagulation is recommended. In this episode of This Is Why with Dr. Busti, we break down a board-style clinical question to explain when anticoagulation should NOT be started in atrial fibrillation. Understanding stroke risk stratification is essential for USMLE, NAPLEX, NP, PA, and medical board exams. This episode walks step-by-step through the reasoning behind anticoagulation decisions using the CHA₂DS₂-VASc scoring system. Topics Covered - CHA₂DS₂-VASc score interpretation - Atrial fibrillation stroke prevention - When anticoagulation is not recommended - AF anticoagulant dosing traps for board exams - Warfarin vs DOAC dosing in AF - Board exam test-taking strategies for AF management  The goal = make medical education easy and clinically relevant. 👉 Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/cha2ds2-vasc-score-atrial-fibrillation-board-question 👉 Get more with a free membership at https://www.thisiswhy.health/ - Access free downloads from our videos  - Access deep dive content from Dr. Busti - Organize content via playlists & collections - Join live Q&A - Receive member newsletters - Coupons & discounts for exam prep resources 👍 If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content. 🔔 Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more! #afib #atrialfibrillation #cha2ds2vasc #anticoagulation #drbusti Disclaimer: This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

    12 min

  2. 2D AGO

    Proctalgia Fugax: Medical Terminology Explained

    What is proctalgia fugax, and why does this term matter in real clinical practice? In this episode of This Is Why, Dr. Busti breaks down the meaning of proctalgia fugax, its etymology, how it has been understood historically, and how healthcare professionals should use the term today. This lesson focuses on concept-based learning, helping clinicians connect the terminology to differential diagnosis, disorders of gut-brain interaction, and the practical question of whether brief anorectal pain fits proctalgia fugax or points to something else. If you want to understand the “why” behind the words we use in medicine, this episode will help you think more clearly about anorectal pain, diagnosis of exclusion, and patient-centered clinical reasoning. The goal = make medical education easy and clinically relevant. 👉 Get more with a free membership at https://www.thisiswhy.health/ - Access free downloads from our videos  - Access deep dive content from Dr. Busti - Organize content via playlists & collections - Join live Q&A - Receive member newsletters - Coupons & discounts for exam prep resources 👍 If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content. 🔔 Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more! #proctalgiafugax #medicalterminology #anorectalpain #clinicalreasoning #drbusti Disclaimer: This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

    13 min

  3. JAN 27

    LAMA (Long-Acting Muscarinic Antagonists) Bronchodilators for COPD

    In this lecture from This is Why, Dr. Busti will explain the COPD maintenance inhalers you’ll actually see in practice. In this pharmacology review, we break down LAMA (long-acting muscarinic antagonist) bronchodilators—one of the most important bronchodilator classes for COPD treatment—so you can confidently understand the drugs, the mechanism, and the real-world clinical use. You’ll learn how to: What LAMA / antimuscarinic bronchodilators are and how they workWhere LAMA inhalers fit in COPD therapy and long-term symptom controlKey differences and practical pearls for common COPD inhalersHigh-yield side effects, contraindications, and patient counseling pointsHow to recognize and avoid common med errors and confusion with inhaler names/classesDrugs covered: Tiotropium (Spiriva)Umeclidinium (Incruse Ellipta)Aclidinium (Tudorza Pressair)Glycopyrrolate (COPD maintenance formulations)The goal = make medical education easy and clinically relevant. Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/lama-bronchodilators-copd-tiopotropium-umeclidinium-pharmacology Get more with a free membership at https://www.thisiswhy.health/ Access free downloads from our videos Access deep dive content from Dr. BustiOrganize content via playlists & collectionsJoin live Q&AReceive member newslettersCoupons & discounts for exam prep resourcesIf this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content. Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more! Disclaimer: This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

    26 min

  4. JAN 27

    SAMA (Short-Acting Muscarinic Antagonists) Bronchodilator Pharmacology

    Short-acting muscarinic antagonists (SAMAs) are a core bronchodilator drug class you’ll see constantly in COPD care. In this lecture from This is Why, Dr. Busti will learn about short-acting muscarinic antagonists (SAMAs) are a core bronchodilator drug class you’ll see constantly in COPD care—and on exams like the NCLEX. In this lecture, you’ll learn exactly how SAMAs work, when to use them, and what safety pearls can help you avoid common clinical pitfalls in COPD. You’ll learn how to: Mechanism of action: muscarinic (M3) blockade → decreased bronchoconstrictionKey drug: ipratropium (Atrovent)Common combinations: ipratropium/albuterol (DuoNeb, Combivent)Clinical uses: COPD maintenance/symptom relief, COPD exacerbation support, select asthma situations (often as add-on therapy in acute care)Routes & devices: MDI vs nebulized treatments, dosing frequency, and practical inhaler/neb pearlsAdverse effects & warnings: dry mouth, cough, urinary retention (BPH), blurry vision/precipitating angle-closure symptoms if sprayed into eyes, and other anticholinergic considerationsHigh-yield comparisons: SAMA vs LAMA (where tiotropium and other long-acting agents fit)The goal = make medical education easy and clinically relevant. Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/sama-short-acting-muscarinic-antagonist-ipratropium-bronchodilator Get more with a free membership at https://www.thisiswhy.health/ Access free downloads from our videos Access deep dive content from Dr. BustiOrganize content via playlists & collectionsJoin live Q&AReceive member newslettersCoupons & discounts for exam prep resourcesIf this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content. Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more! Disclaimer: This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

    24 min

  5. JAN 27

    GLP-1 Receptor Agonists (eg, Semaglutide) Diabetes Pharmacology Review

    Understand the GLP-1 receptor agonists—and why agents like semaglutide (Ozempic/Wegovy/Rybelsus), liraglutide, dulaglutide, and exenatide have become one of the most talked-about type 2 diabetes medications in modern practice. In this lecture from This is Why, Dr. Busti will break GLP-1s down in a clear, clinically relevant way so you can confidently explain how they work, when to use them, and what to watch for clinically when managing patients with type 2 diabetes and/or obesity. You’ll learn how to: - Mechanism of action: incretin mimetic effects (GLP-1) and what that means for glucose control - Therapeutic use: where GLP-1 agonists fit in type 2 diabetes (T2DM) treatment strategies - Key agents: semaglutide, plus comparisons to liraglutide, dulaglutide, and exenatide - Benefits & counseling pearls: weight effects, dosing basics, and practical patient education - Adverse effects & precautions: the high-yield safety points clinicians get tested on (and seen in clinical practice) The goal = make medical education easy and clinically relevant. Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/glp-1-receptor-agonists-semaglutide-dulaglutide-liraglutide-diabetes-pharmacology-review Get more with a free membership at https://www.thisiswhy.health/ - Access free downloads from our videos  - Access deep dive content from Dr. Busti - Organize content via playlists & collections - Join live Q&A - Receive member newsletters - Coupons & discounts for exam prep resources If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content. Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more! #glp1receptoragonist #semaglutide #type2diabetes #diabetesmedications #busti Disclaimer: This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

    46 min

  6. JAN 27

    Insulin Types: Rapid, NPH, Basal for Diabetes - Pharmacology Review

    Insulin doesn’t have to be confusing when learning how to treat Type 1 and Type 2 diabetes mellitus. In this lecture from This is Why, Dr. Busti will explain how to quickly recognize insulin types, predict onset/peak/duration, and apply basal–bolus dosing concepts to real-world Type 1 and Type 2 diabetes care. You’ll learn how to: - How to identify rapid-, short-, intermediate-, and long-acting insulin for Diabetes - The difference between basal insulin vs bolus (mealtime) insulin - How basal–bolus regimens work (plus common pitfalls) - Practical tips for insulin administration, timing with meals, and avoiding errors - High-yield clinical points you’re likely to see in courses and on exams Insulins covered (for memorization + exam success): - Rapid-acting: insulin lispro, aspart, glulisine - Short-acting: regular insulin - Intermediate-acting: NPH insulin - Long-acting / basal: insulin glargine, detemir, degludec - Premixed options: 70/30 mixes (NPH/regular and related premixed products) The goal = make medical education easy and clinically relevant. Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/insulin-types-diabetes-pharmacology-review Get more with a free membership at https://www.thisiswhy.health/ - Access free downloads from our videos  - Access deep dive content from Dr. Busti - Organize content via playlists & collections - Join live Q&A - Receive member newsletters - Coupons & discounts for exam prep resources If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content. Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more! #insulin #diabetes #insulintypes #diabetespharmacology #busti Disclaimer: This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

    1h 1m

  7. JAN 27

    LABA (Long-Acting Beta Agonists) Bronchodilators for Asthma & COPD

    In this lecture from This is Why, Dr. Busti will explain how Long-Acting Beta Agonists (LABAs) work, where they fit in therapy for the management of asthma and COPD. You’ll learn how to: - Mechanism of action: beta-2 receptor activation → bronchodilation (airway smooth muscle relaxation) - Clinical use: LABAs in COPD maintenance vs asthma (must be combined with ICS) - Onset/duration differences and practical inhaler considerations - Adverse effects & warnings: tachycardia, tremor, hypokalemia, paradoxical bronchospasm, and key safety concepts - Therapeutic combos: ICS/LABA combination inhalers and where they fit (including common guideline concepts) LABA drugs discussed for SEO/review: - Salmeterol - Formoterol - Vilanterol - Olodaterol - Indacaterol The goal = make medical education easy and clinically relevant. Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/laba-long-acting-beta-agonists-asthma-copd-bronchodilators-pharmacology Get more with a free membership at https://www.thisiswhy.health/ - Access free downloads from our videos  - Access deep dive content from Dr. Busti - Organize content via playlists & collections - Join live Q&A - Receive member newsletters - Coupons & discounts for exam prep resources If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content. Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more! #LABA #LongActingBetaAgonist #Asthma #Bronchodilators #busti Disclaimer: This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

    36 min

  8. JAN 27

    Meglitinides (Nateglinide & Repaglinide): Diabetes Pharmacology Review

    Meglitinides (Nateglinide & Repaglinide) can feel like the “forgotten” oral diabetes drugs—but they show up on exams, in real-world medication histories, and in questions about postprandial glucose control and hypoglycemia and weight gain risk. In this lecture from This is Why, Dr. Busti will explain the meglitinides in a clear, clinically relevant way so you can recognize them quickly and use the concepts confidently in the context of Type 2 diabetes (T2DM). You’ll learn how to: - Meglitinides overview: where they fit in type 2 diabetes (T2DM) therapy - Drug names you must know: repaglinide and nateglinide - Mechanism of action: how these insulin secretagogues stimulate insulin release (the KATP channel connection) - Onset/duration & dosing concept: why they’re considered short-acting / prandial glucose agents - Therapeutic application: targeting postprandial hyperglycemia and when they may (or may not) be chosen - Adverse effects & safety: hypoglycemia, weight considerations, and key patient counseling points The goal = make medical education easy and clinically relevant. Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/meglitinides-repaglinide-nateglinide-diabetes-pharmacology-review Get more with a free membership at https://www.thisiswhy.health/ - Access free downloads from our videos  - Access deep dive content from Dr. Busti - Organize content via playlists & collections - Join live Q&A - Receive member newsletters - Coupons & discounts for exam prep resources If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content. Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more! #meglitinides #repaglinide #nateglinide #type2diabetes #busti Disclaimer: This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

    13 min
See All (77)

Ratings & Reviews

5
out of 5
3 Ratings

About

This Is Why exists to help medical professionals understand the why behind the decisions they make every day in patient care. Our approach is about integrating evidence, clinical relevance and real-world application so that what your learn connects directly with the patients you serve. 

Information

  • Creator
    Anthony Busti, MD, PharmD, MSc, FNLA, FAHA
  • Years Active
    2025 - 2026
  • Episodes
    77
  • Rating
    Clean
  • Copyright
    © 2026 This Is Why with Dr. Busti
  • Show Website
    This Is Why with Dr. Busti